News Release


Printer Friendly Version View printer-friendly version
<< Back
Illumina Names Aimee Hoyt Chief People Officer, Bringing 20+ Years of Senior Human Resources Leadership from Global Technology Companies

SAN DIEGO--(BUSINESS WIRE)--Dec. 11, 2017-- Illumina, Inc. (NASDAQ:ILMN) today announced Aimee Hoyt, an accomplished and strategic talent leader, will head its human resources team. Ms. Hoyt will join as Senior Vice President and Chief People Officer (CPO), starting January 8, 2018, and will be responsible for leading all aspects of the company’s HR strategies, reporting to the CEO.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005352/en/

Aimee Hoyt (Photo: Business Wire)

Aimee Hoyt (Photo: Business Wire)

“After a global search, we are thrilled to have Aimee join Illumina, and believe she is the right person to help us continue on our path as an innovative leader in people practices,” said Francis deSouza, President and Chief Executive Officer of Illumina. “Adding a CPO of Aimee’s caliber is important to support Illumina’s continued growth. She has a successful track record of leading workforce transformation, driving business growth and creating high-impact teams.”

Ms. Hoyt has held senior positions at some of the world’s best-known technology companies including Hewlett-Packard, Cisco and Sun Microsystems. Most recently, she was the Chief Human Resources Officer at Rackspace, a leading managed cloud computing company, in San Antonio, Texas. She led the HR team and was responsible for helping build, align and develop high-performing global teams. During her tenure, Rackspace was recognized as one of Fortune’s 100 Best Companies to Work For, Top 30 Best Places in Tech and Great Places to Work for Millennials. Ms. Hoyt earned a master’s in human resource development from the Rochester Institute of Technology.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, and to deploy new products, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-882-2172
IR@illumina.com
or
Media:
Jen Carroll
858-882-6822
PR@illumina.com